 This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy Pexa-Vec followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy. 